The legal overhang on Abbott Labs has been real, even if shares have found some traction in recent months. Bottom line Abbott Labs still faces other cases over its specialized formulas across the country, but Thursday night's win is significant. Abbott shares traded around 22 times forward earnings estimates Friday, below their five-year average of 24, according to FactSet. With victory in hand, Abbott Labs will now begin the next phase of its legal fight on much stronger ground. As a subscriber to the CNBC Investing Club with Jim Cramer, you will receive a trade alert before Jim makes a trade.

---

Persons: Mead Johnson, Benckiser, Louis Children's, Abbott, Mead, —, Scott Stoffel, ABT, — Mead Johnson, Jim Cramer, Cramer, Jim Cramer's, Jim, Stacey Wescott Organizations: Abbott Laboratories, Club, Abbott Labs, NEC, CNBC, Abbott, and Drug Administration, Centers for Disease Control, National Institutes of Health, FDA, CDC, NIH, Chicago Tribune, Tribune, Service, Getty Locations: Missouri, St